Fondation Ophtalmologique de Rothschild
Paris, 75019, France
Location status: Recruiting
NCT Number: NCT05051072
Essential trigeminal neuralgia is the most common facial pain. In forms resistant to drug and disabling treatments, surgical treatment may be offered to the patient. The type of intervention will be conditioned by the presence or absence of a vasculo-nervous conflict objectified by MRI(Magnetic resonance imaging) Morphological MRI with contrast injection does not always allow an accurate assessment of trigeminal nerve damage in patients with essential facial neuralgia. Despite advances in the anatomical definition of high-resolution MRI, the correlation between a vascular conflict visible on MRI and present during surgery and prolonged postoperative clinical improvement remains insufficient These data raise the question of additional imaging sequences to assess the distressing characteristics of NT in addition to the usual anatomical criteria for compression By performing during morphological MRI two additional sequences, one in diffusion tensor (DTI) and one in resting state (fMRI), we could better characterize the achievement of NT
The contribution of new imaging sequences in the context of essential trigeminal neuralgia treated with microvascular decompression (MVD) would:
1/improve the diagnostic criteria for suffering and compression of the NT (trigeminal nerve) 2 / define objective prognostic criteria for the effectiveness of surgery, particularly in the context of unusual clinical symptoms or moderate conflict on MRI (Magnetic resonance imaging) 3 / to analyze more precisely the causes of recurrence at a distance from surgery and help in the decision of re-intervention Our main hypothesis: the addition of a diffusion tensor sequence and sequences (allowing functional brain analysis) in addition to standard anatomical MRI in the assessment of a vasculo-nervous conflict would allow us to better characterize involvement of the trigeminal nerve in essential facial neuralgia. It also helps guide therapeutic management and surgical indications.
This is a prospective, monocentric cohort study. It will be offered to patients referred to neurosurgery or to the pain assessment and treatment center for assessment and management of a neuralgia of the essential trijumeau unilateral.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Paris, 75019, France
Location status: Recruiting
Name:
MRI in morphological sequence, diffusion tensor and resting functional
Description:
The MR exam will be performed on the Neuroradiology 3 Tesla (Philips) MR according to the following protocol:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Assessment of the trigeminal nerve by diffusion tensor MRI and in "resting state" in the context of essential neuralgia
Time frame: Day 0 - inclusion
Describe in patients with unilateral essential trigeminal neuralgia, the micro-structural modifications of the trigeminal nerve observed from data from the DTI sequence compared to the healthy contralateral side
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: SENSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07216547
Cranial Nerve Diseases, Facial Nerve Diseases
Newark, New Jersey, United States
View Trial DetailsNCT07596485
Cranial Nerve Diseases, Facial Nerve Diseases
Sherbrooke, Canada
View Trial DetailsNCT06724029
Aneurysm, Aneurysms
Bergamo, BG, Italy
View Trial DetailsNCT02910323
Brain Diseases, Central Nervous System Diseases
Houston, Texas, United States
View Trial Details